Ideaya eye cancer drug meets main goal of mid-to-late-stage trial
13/04/2026 11:04
April 13 (Reuters) - Ideaya Biosciences IDYA.O said on Monday its drug for a type of eye cancer met the main goal of a mid-to-late-stage trial, after showing improvement in patients' survival without progression of the disease. (Reporting by Puyaan Singh in Bengaluru; Editing by Sahal Muhammed) ((Puyaan.Singh@thomsonreuters.com;))
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj